Thiamine deficiency appears uncommon in patients with Myeloproliferative Neoplasms

Br J Haematol. 2017 Jul;178(2):338-340. doi: 10.1111/bjh.14128. Epub 2016 May 2.

Authors

Natalia Curto-García¹, Claire N Harrison², Donal P McLornan², Deepti H Radia²

Affiliations

¹ Department of Haematology, Royal Free London NHS Foundation Trust, London, UK.
² Department of Haematology, Guy's and St. Thomas NHS Foundation Trust, London, UK.

PMID: 27135305
DOI: 10.1111/bjh.14128

No abstract available

Keywords: JAK1/2 inhibitor; fedratinib; myelofibrosis; thiamine.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Myeloproliferative Disorders / blood*
Myeloproliferative Disorders / complications*
Myeloproliferative Disorders / diagnosis
Myeloproliferative Disorders / drug therapy
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects*
Thiamine / blood*
Thiamine Deficiency / blood*
Thiamine Deficiency / diagnosis
Thiamine Deficiency / etiology*

Substances

Protein Kinase Inhibitors
Thiamine